The clinical potential of novel erythropoiesis stimulating protein

Abstract

Novel erythropoiesis stimulating protein (NESP) is a supersialyated analogue of endogenous erythropoietin or recombinant human erythropoietin (rhuEPO). It contains a total of five N-linked consensus carbohydrate binding sites in the native protein. NESP has a higher molecular weight due to an increased content of carbohydrates, which, however, has no meaningful influence on the binding to and activation of the erythropoietin receptor. The major difference in comparison to rhuEPO is the up to threefold increase of the terminal half-life of NESP, which allows for less frequent dosing of NESP. Several clinical studies have shown that NESP is as safe and efficient as rhuEPO in correcting renal anaemia and in the maintenance therapy of renal anaemia.

• anaemia of chronic disease
• ARANESP
• cancer
• chemotherapy
• darbepoetin alfa
• erythropoietin
• haemodialysis
• NESP
• peritoneal dialysispharmacodynamics
• pharmacokinetics
• renal anaemia